Replimune Group Inc
Research Replimune Group Inc (REPL) on Bullrun: market cap USD 1.33B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerREPL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.33B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 73.22M
- Free cash flow-USD 56.17M
Valuation Snapshot
latest market cap is USD 1.33B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 247.30M | -USD 198.94M | n/a | -3.07 | USD 111.12M | USD 46.38M | USD 415.84M |
| FY2024 | USD 0 | -USD 215.79M | -USD 191.13M | n/a | -3.24 | USD 74.46M | USD 44.81M | USD 374.51M |
| FY2023 | USD 0 | -USD 174.28M | -USD 130.32M | n/a | -2.99 | USD 146.59M | USD 28.65M | USD 555.29M |
| FY2022 | n/a | -USD 118.04M | -USD 84.52M | n/a | -2.26 | USD 105.95M | USD 0 | USD 411.23M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.33B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 774.02M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 932.58M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 497.87M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.54B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.28B | n/a | n/a | n/a |
About Replimune Group Inc
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Replimune Group Inc's market cap?
Replimune Group Inc's market capitalization is USD 1.33B.
What does Replimune Group Inc do?
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors.